Report on nationwide pooled data and cohort investigation in UFT phase II study

摘要: UFT is a compound in which futraful (FT) and uracil are combined at ratio of 1:4. was given orally daily dose 300–600 mg phase II study. Pooled data on study 438 evaluable patients, 104 institutions revealed response carcinoma the stomach (27.7%), pancreas (25.0%), gallbladder bile duct liver (19.2%), colon rectum breast (32.0%), lung (7.0%). The mainly gastrointestinal toxicity resulted anorexia (24.3%), nausea vomiting (12.5%), diarrhea (11.8%). On other hand, hematological rare mild. To analyze lifeprolonging effect therapy, cohort carried out cases collected 5 years after commencement therapy. 50% survival time for 185 patients with gastric cancer days. corresponding times 54 colorectal 49 were 227 505 days, respectively. A historical comparative FT, administered same equal evaluation, that had significantly better than FT without more pronounced side effects equivalent schedule. In conclusion, can be considered useful agent against cancers over broad spectrum, especially cancer.